<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3104">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355494</url>
  </required_header>
  <id_info>
    <org_study_id>ECU-COV-401</org_study_id>
    <nct_id>NCT04355494</nct_id>
  </id_info>
  <brief_title>SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19</brief_title>
  <official_title>SOLIRIS® (Eculizumab) for the Treatment of Participants With Coronavirus Disease 2019 (COVID 19) - An Expanded Access Program for Hospital-based Emergency Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This protocol provides access to eculizumab treatment for participants with severe COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multicenter, Expanded Access Program (EAP) to allow participants with&#xD;
      a confirmed diagnosis of SARS-CoV-2 infection, and a clinical presentation consistent with&#xD;
      COVID-19 severe pneumonia, acute lung injury, or ARDS to be treated with eculizumab.&#xD;
      Participants admitted to a designated hospital facility who qualify for emergency treatment&#xD;
      will be administered eculizumab up to 7 times during their treatment course (5 mandatory&#xD;
      doses and up to 2 optional doses, per Investigator assessment).&#xD;
&#xD;
      The EAP consists of a Screening Period of up to 7 days, a 4-week Treatment Period, a final&#xD;
      in-hospital assessment on Day 29 or day of discharge, whichever occurs first, and 3 monthly&#xD;
      safety follow up visits (to be conducted as a telephone call if the participant has been&#xD;
      discharged from the hospital or an in-person visit if the participant is still hospitalized).&#xD;
&#xD;
      For each participant, the total duration of the program is anticipated to be 4.5 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>COVID-19</condition>
  <condition>Pneumonia, Viral</condition>
  <condition>Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>eculizumab</intervention_name>
    <description>Eculizumab at doses of 900-1200 mg will be administered intravenously (up to 7 doses)</description>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females ≥ 18 years of age and ≥ 40 kg at the time of providing informed&#xD;
             consent.&#xD;
&#xD;
          2. Confirmed diagnosis of SARS-CoV-2 infection presenting as severe COVID-19 requiring&#xD;
             hospitalization&#xD;
&#xD;
          3. Symptomatic, bilateral pulmonary infiltrates confirmed by CT or X-ray at Screening or&#xD;
             within the 7 days prior to Screening&#xD;
&#xD;
          4. Severe pneumonia, acute lung injury, or ARDS requiring oxygen supplementation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of SARS-CoV-2 infection presenting as mild to moderate COVID-19,&#xD;
             even if the participant is hospitalized&#xD;
&#xD;
          2. Participant is not expected to survive more than 24 hours&#xD;
&#xD;
          3. Participant has an unresolved Neisseria meningitidis infection&#xD;
&#xD;
          4. Hypersensitivity to murine proteins or to one of the excipients of Soliris&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals Inc.</last_name>
    <phone>1-855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Newton-Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Garches Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute lung injury</keyword>
  <keyword>acute respiratory distress syndrome</keyword>
  <keyword>antibodies, monoclonal, humanized</keyword>
  <keyword>complement inhibition</keyword>
  <keyword>COVID-19</keyword>
  <keyword>eculizumab</keyword>
  <keyword>emergency treatment</keyword>
  <keyword>expanded access program</keyword>
  <keyword>hospitalization</keyword>
  <keyword>pneumonia</keyword>
  <keyword>severe acute respiratory syndrome</keyword>
  <keyword>severe acute respiratory syndrome coronavirus 2</keyword>
  <keyword>severe pneumonia</keyword>
  <keyword>Soliris</keyword>
  <keyword>viral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

